Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct 4:14:158.
doi: 10.1186/1471-2466-14-158.

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study

Henrik Watz  1 , Felix Krippner, Anne Kirsten, Helgo Magnussen, Claus Vogelmeier
Affiliations
Randomized Controlled Trial

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study

Henrik Watz et al. BMC Pulm Med. .

Abstract

Background: Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured physical activity during treatment with indacaterol 150 μg and matched placebo.

Methods: We performed a randomized, three-period, cross-over study (21 days of treatment separated by two wash-out periods of 13 days) with indacaterol 150 μg or matching placebo and tiotropium 18 μg. Lung function was assessed by body plethysmography and spirometry. Physical activity was measured for one week by a multisensory armband at the end of both treatment periods with indacaterol/matched placebo. The primary endpoint was peak inspiratory capacity at the end of each treatment period.

Results: 129 patients (mean age, 61 years; mean post-bronchodilator FEV1, 64%), were randomized and 110 patients completed the study. Peak inspiratory capacity was 0.22 L greater with Indacaterol at day 21 compared to placebo (p < 0.001). Similar results were observed for tiotropium. Both bronchodilators also significantly improved other parameters of lung hyperinflation compared with placebo. All parameters of physical activity were significantly increased during treatment with indacaterol versus placebo.

Conclusions: Indacaterol 150 μg improved lung hyperinflation in patients with moderate COPD, which was associated with an increase of physical activity.

Trial registration: ClinicalTrials.gov registration number: NCT01012765.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of indacaterol and tiotropium versus placebo on peak inspiratory capacity (IC) on Day 21. ***p < 0.001 vs placebo; #non-inferiority to tiotropium. Data are least square mean ± 95% CI for FAS population (n = 129).
Figure 2
Figure 2
Effect of indacaterol and tiotropium versus placebo in trough inspiratory capacity (IC) on Day 20. ***p < 0.001 vs placebo; #non-inferiority to tiotropium. Data are least square mean ± 95% CI for FAS population (n = 129).
Figure 3
Figure 3
Effect of indacaterol on physical activity during treatment. (a) Steps per day (n=83) (b) Minutes of at least moderate physical activity (n=83).
See this image and copyright information in PMC

References

    1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. doi: 10.1164/rccm.201204-0596PP. - DOI - PubMed
    1. Ferguson GT. Why does the lung hyperinflate? Proc Am Thorac Soc. 2006;3:176–179. doi: 10.1513/pats.200508-094DO. - DOI - PubMed
    1. O’Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007;4:225–236. doi: 10.1080/15412550701480455. - DOI - PubMed
    1. Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, Lopez-Collazo E, Alvarez-Sala R. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med. 2009;180:506–512. doi: 10.1164/rccm.200812-1873OC. - DOI - PubMed
    1. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33:262–272. doi: 10.1183/09031936.00024608. - DOI - PubMed
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/14/158/prepub

Publication types

MeSH terms

Associated data